Factor VIII inhibitors in hemophilia A treated with emicizumab: longitudinal follow-up of outcomes

BACKGROUND: Using emicizumab in lieu of immune tolerance induction (ITI) for patients with hemophilia A (HA) and factor (F)VIII inhibitors has been well described. However, decisions regarding ITI initiation, regimen, and preservation of tolerance remain to be elucidated. OBJECTIVES: To study the co...

Descripción completa

Detalles Bibliográficos
Autores principales: Levy-Mendelovich, Sarina, Atia, Nitzan, Budnik, Ivan, Barg, Assaf Arie, Avishai, Einat, Cohen, Omri, Brutman-Barazani, Tami, Livnat, Tami, Kenet, Gili
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394563/
https://www.ncbi.nlm.nih.gov/pubmed/37538499
http://dx.doi.org/10.1016/j.rpth.2023.100278

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394563/
https://www.ncbi.nlm.nih.gov/pubmed/37538499
http://dx.doi.org/10.1016/j.rpth.2023.100278

Ejemplares similares